One thing we rarely discuss is the selling price f

One thing we rarely discuss is the selling price for Leronlimab per dose. As much as Leronlimab in some indications is the only drug that might work and there is no completion, there are other indications where it may be the best or better than what is available. Focusing on the performance is important, but I wonder if pricing has a roll in making the BP industry notice this drug. What if we price Leronlimab cheaper, given the huge population that is just suffering from MASH?

"8 weeks * 1,000,000 patients * $1,000 per vial = $8 billion over 8 weeks for treating merely a very tiny proportion of the patient population out there and only treating them for 1/2 of 1 course."

if we use this example, and add that Cytodyn may have spent $500 million on the development of Leronlimab (just an estimate) we can see that the cost per dose for the million patient for 8 doses is about $63 per to fully pay for development. I have no idea what it costs to actually make Leronlimab but if the dose could be less than $200 per dose we might have real threat to any other drug in this indication.

I would think BP would be not only concerned about greater effectiveness of Leronlimab but also the willingness to sell it for a low cost by Cytodyn could really make BP want to jump in long before it hits the market. just a thought.